This is an aggregated industry headline. Read the full story at FiercePharma →
Peptide adcomm Day 2: Emideltide voted down in panel's 1st pushback
As outside experts gathered for a second day to discuss adding certain popular-yet-unapproved peptides to the U.S.' bulk compounding list, the first to go up against a vote did not fare as well as those assessed Thursday.
By FiercePharma
· Jul 26, 2026
· via FiercePharma
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFierceBiotech ↗
As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial tea…
The WeekBriefing
Three items stood out this week: U.S. import tariffs on generic drugs, Samsung Biologics pursuing a $1.8 billi…
The WeekFiercePharma ↗
A survey of 36 U.S. gastroenterologists found that significant treatment gaps remain in the growing IBD drug m…